Skip to main content

Crestline Management, L.P.

13F filer · CIK 0001536054
Reported May 15, 2026
Net seller this quarter
13F portfolio value$535MU.S. long equity reported on 13F
Positions30 new · 0 closed
Net flow last quarter-$12.9MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q1 2026Reported May 15, 20263 positions
DNLIDenali Therapeutics Inc.$42.4M91.74%1.39%-21.4%Q4 2017
SANASana Biotechnology, Inc.$2.18M4.70%0.28%-38.1%Q2 2021
EGHT8x8 Inc$1.64M3.56%0.70%0.0%Q3 2016
Q4 2025Reported Feb 17, 20263 positions
DNLIDenali Therapeutics Inc.$46.4M87.02%1.80%-17.6%Q4 2017
SANASana Biotechnology, Inc.$4.97M9.32%0.46%-33.0%Q2 2021
EGHT8x8 Inc$1.95M3.66%0.71%Not reportedQ3 2016
Q3 2025Reported Nov 14, 20253 positions
DNLIDenali Therapeutics Inc.$49.5M85.26%2.33%-11.7%Q4 2017
SANASana Biotechnology, Inc.$6.46M11.13%0.69%-24.8%Q2 2021
EGHT8x8 Inc$2.1M3.62%0.71%Not reportedQ3 2016
Q2 2025Reported Aug 14, 20253 positions
DNLIDenali Therapeutics Inc.$54M86.33%2.65%-7.2%Q4 2017
SANASana Biotechnology, Inc.$6.61M10.56%1.05%-13.3%Q2 2021
EGHT8x8 Inc$1.94M3.10%0.73%Not reportedQ3 2016
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.